Cyclopharm is an established Australian radiopharmaceutical company servicing the global medical community since 1986.
Cyclopharm is a company in the diagnostic imaging field specialising in lung health. We achieve this positioning through our proprietary medical device and pharmaceutical products under the name of Technegas™ which has become the industry gold-standard in diagnostic functional lung imaging technology.
We distribute our products in 60 countries throughout the world with over 1500 nuclear medicine departments utilising Technegas™. To date, over 4.2 million patient procedures are recorded.
Technegas™ is a structured ultra-fine dispersion of radio-labelled carbon, produced by using dried Technetium-99m in a carbon crucible, micro furnaced for a few seconds at around 2,750°C. The resultant gaseous substance is inhaled by the patient via a breathing apparatus, which then allows multiple views and tomographic imaging with a nuclear medicine camera for superior functional imaging of the alveolar spaces of the lungs.
Macquarie Medical Imaging
Cyclopharm formed a joint venture with Alfred Health Solutions and Macquarie University Hospital to provide all imaging services on-site at the hospital. The new venture named Macquarie Medical Imaging (MMI) represents a rare strategic opportunity to provide a fully aligned and integrated diagnostic, therapeutic and research platform. MMI offers a range of diagnostic radiology, interventional radiology, nuclear medicine and molecular imaging services for inpatient and outpatients.
The combination of state-of-the art imaging equipment, a GE cyclotron located on the grounds of MUH, leading surgeons, clinicians and academics will ensure that MMI will become the leading centre of imaging excellence.